EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

Trial Profile

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Valsartan
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms HFN-LIFE; LIFE
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Mar 2017 Planned End Date changed from 1 Feb 2019 to 17 Mar 2019.
    • 08 Mar 2017 Planned primary completion date changed from 1 Feb 2019 to 3 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top